Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.53
+0.11002.03%
Post-market: 5.530.00000.00%19:30 EDT
Volume:621.10K
Turnover:3.43M
Market Cap:334.36M
PE:-1.19
High:5.64
Open:5.40
Low:5.38
Close:5.42
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.92
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.52
PE(LYR):-1.48

Loading ...

Vanda Pharmaceuticals Inc - Nereus Available at $85 per Dose Cash-Pay

THOMSON REUTERS
·
May 04

Vanda Pharmaceuticals Announces U.S. Commercial Availability of Nereus™ (Tradipitant), the First New Pharmacologic Treatment for People With Motion Sickness in More Than 40 Years

THOMSON REUTERS
·
May 04

BRIEF-Vanda Pharmaceuticals US Availability Of Nereus For People With Motion Sickness

Reuters
·
May 02

Vanda Pharmaceuticals announces commercial availability for Nereus

TIPRANKS
·
May 02

Vanda Pharmaceuticals: Standard List Price of $255 per Dose for Nereus

THOMSON REUTERS
·
May 02

Vanda Pharmaceuticals: Patients With Valid Prescription Can Access Nereus at Cash-Pay Price of $85 per Dose

THOMSON REUTERS
·
May 02

Vanda Pharmaceuticals Announces U.S. Commercial Availability of Nereus™ (Tradipitant), the First New Pharmacologic Treatment for People With Motion Sickness in More Than 40 Years

THOMSON REUTERS
·
May 02

Vanda Pharma to report first-quarter results after market close, host conference call

Reuters
·
Apr 30

Vanda publishes phase III imsidolimab trial results for generalized pustular psoriasis in NEJM Evidence

Reuters
·
Apr 29

Vanda Pharmaceuticals director Duncan files initial beneficial ownership statement

Reuters
·
Apr 25

Vanda Pharmaceuticals announces annual shareholder meeting webcast

Reuters
·
Apr 24

Vanda Pharmaceuticals Adds Independent Director to Strengthen Board

TIPRANKS
·
Apr 23

Vanda Pharmaceuticals appoints Charles Duncan to board of directors

Reuters
·
Apr 23

Vanda Pharmaceuticals Appoints DR. Charles Duncan to Its Board of Directors

THOMSON REUTERS
·
Apr 23

Vanda files Form 3 for Senior VP, Medical Director Christos Polymeropoulos

Reuters
·
Apr 14

Vanda VP, Chief People Officer Scott Laverne Howell files initial beneficial ownership statement

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
Apr 10

Vanda urges FDA to drop proposal extending statutory drug review timelines

Reuters
·
Apr 09

Vanda Pharmaceuticals Inc - Proposal Would Eliminate FDA 180-Day Nda Review Requirement

THOMSON REUTERS
·
Apr 09